BreastCancerResTreat(2015)149:269–275DOI10.1007/s10549-014-3240-z
EPIDEMIOLOGY
Fulvestrantandmalebreastcancer:apooledanalysis
FloraZagouri TheodorosN.Sergentanis
DimosthenisChrysikos Meletios-AthanasiosDimopoulosTheodoraPsaltopoulou
Received:10November2014/Accepted:10December2014/Publishedonline:18December2014ÓSpringerScience+BusinessMediaNewYork2014
AbstractMalebreastcancerisanuncommonmalig-nancy;littleisknownregardinghormonalmanipulationsfortamoxifen-resistantmalebreastcancerpatients.Thisisthe rstpooledanalysisoftheliteraturetosynthesizeallavailabledataandtoevaluatetheef cacyandsafetyoffulvestrantinmalebreastcancer.Thisstudywasper-formedinaccordancewiththePRISMAguidelines.Allstudiesthatexaminedtheef cacyoffulvestrantinmalebreastcancer,regardlessofsamplesize,wereconsideredeligible.Thesearchstrategyretrieved31articles;ofthese, vearticleswereeligible(23patients)forthispooledanalysis.Themeanageofthestudysamplewas63.1years.Adjuvanthormonaltreatmentwasadministeredin87.5%ofcases.Fulvestrantwasgivenas rstorsecondlinein40%ofpatients,whileasthirdlineorbeyondin60%ofpatients.79.0%ofpatientsatfulvestrantadministrationhadvisceralmetastases.Regardingbestresponse,in26.1%PRwasachieved,in47.8%ofcasesSDwasrecorded,whereasin26.1%ofpatientsPDwasnoted.ThemedianPFSwasequalto5months.Nograde3and4adverseeventswererecorded;ofnote,hot asheswerereportedin18.2%ofmalebreastcancerpatients.Fulve-strantmaypotentiallyplayapromisingroleintheoptimaltherapeuticstrategyformalepatientswithbreastcancerdiagnosis.However,furtherclinicalandpharmacokinetic
investigationsaremorethanwarrantedbeforefulvestrantusebecomesacommonpracticeinmalebreastcancerpatients.
KeywordsMalebreastcancerÁFulvestantÁHormonaltreatmentÁTherapyÁPooledanalysis
Introduction
Malebreastcancerisanuncommonmalignancyanditaccountsapproximatelyforlessthanonepercentofalldiagnosedbreastcancers[1].Duetotherarityofthedis-easeinmen,clinical-trialreportsarelackingandconse-quently,treatmentrecommendationsinmenaremainlyextrapolatedfromtheresultsoftrialsinwomen.Accordingtocurrentclinicalguidelines,tamoxifenisthegoldstan-dardintheadjuvantendocrinetherapyofmalebreastcancerandplaysaputativeroleinthemetastaticsetting[2–4].However,littleisknownregardinghormonalmanipulationsfortamoxifen-resistantmalebreastcancerpatients.
Fulvestrantisapureestrogenreceptor(ER)antagonistorselectiveERdown-regulator;itbindscompetitivelytoERsinbreastcancercells,leadingtoERdeformationanddecreasedbindingofestrogen[5].AfterphaseIIItrials,thatdemonstratedsimilaref cacyalongwithanacceptablesafetypro leforfulvestrant250mgcom-paredwithanastrozole,aswellassubsequenttrialsevaluatingfulvestrant250versus500mg,currentlyful-vestrant500mghasbeenapprovedastreatmentinpostmenopausalwomenwithadvancedhormonerecep-tor-positivebreastcancerwhohadprogressedorrecurredafterpriorantiestrogentherapy(tamoxifenand/orAI)[6,7].Thereisnoprospectiveclinicaltrialwiththeuse
F.Zagouri(&)ÁD.ChrysikosÁM.-A.Dimopoulos
DepartmentofClinicalTherapeutics,MedicalSchool,AlexandraHospital,UniversityofAthens,VasSo asAve&Louroustr,11521Athens,Greece
e-mail: orazagouri@yahoo.co.uk
T.N.SergentanisÁT.Psaltopoulou
DepartmentofHygiene,EpidemiologyandMedicalStatistics,MedicalSchool,UniversityofAthens,Athens,Greece
123
(×200)?From?Zagouri?et? al?BMC?Cancer?2010 Hsp90?Expression?in?Breast?Cancers?by?protein? expression?analysis?(AQUA)?From?Pick?et?al?Cancer? ...
Greece? (Zagouri? F);? and? Department?of?Surgery,?Red?Cross?Hospital,?Athens,?Greece?(Karaliotas?K) Corresponding? Author:? Flora? Zagouri,? MD,? ...
A Case Study of an in Situ Botanical Garden in Zagori, Greece_电子/电路_工程科技_专业资料。Journal ofAgricultural Science and Technology B 3(2 ...
热门文档